Rigel Pharmaceuticals | RIGL - Trade Debtors


Rigel Pharmaceuticals reported $28.9M in Trade Debtors for its fiscal quarter ending in June of 2024.





Trade Debtors Change Date
Agenus USD 22.34M 107K Mar/2026
Amgen USD 10.23B 1.09B Jun/2026
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 8.56M 7.13M Jun/2026
AstraZeneca USD 18.86B 972M Jun/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Celldex Therapeutics USD 230K 0 Jun/2026
Daiichi Sankyo JPY 676.92B 19.03B Jun/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Halozyme Therapeutics USD 453.33M 4.66M Jun/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
Karyopharm Therapeutics USD 23.36M 2.82M Mar/2026
Ligand Pharmaceuticals USD 54.8M 6.25M Mar/2026
MacroGenics USD 10.42M 2.95M Mar/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Pfizer USD 16.19B 19M Jun/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Veracyte USD 54.18M 4.06M Jun/2026